Charles L Campbell

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi request reprint New treatment options for acute coronary syndromes
    Charles L Campbell
    University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T Wethington Bldg, Lexington, KY 40536 0200, USA
    Am J Manag Care 12:S435-43. 2006
  2. ncbi request reprint Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
  3. doi request reprint Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
    J Thromb Thrombolysis 31:139-45. 2011
  4. pmc Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and Lexington Veterans Administration Hospital, Lexington, Kentucky, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
  5. doi request reprint G-protein-coupled receptors as signaling targets for antiplatelet therapy
    Susan S Smyth
    Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 29:449-57. 2009
  6. ncbi request reprint Optimal management of hypertension in patients with ischemic heart disease
    Debabrata Mukherjee
    Gill Heart Institute and the Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Cardiovasc Hematol Agents Med Chem 7:198-205. 2009
  7. pmc Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care?
    Eric L Wallace
    Division of Cardiovascular Medicine, Gill Heart Institute, and the College of Public Health, University of Kentucky, Lexington, KY 40536, USA
    South Med J 106:391-8. 2013
  8. pmc Oral fluids that detect cardiovascular disease biomarkers
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012
  9. ncbi request reprint Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists
    Alison L Bailey
    Gill Heart Institute at University of Kentucky and Lexington Veterans Administration Hospital, Lexington, KY, USA
    Curr Drug Targets 12:1805-12. 2011
  10. pmc Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009

Detail Information

Publications14

  1. ncbi request reprint New treatment options for acute coronary syndromes
    Charles L Campbell
    University of Kentucky, Gill Heart Institute, 900 S Limestone St, 326 Charles T Wethington Bldg, Lexington, KY 40536 0200, USA
    Am J Manag Care 12:S435-43. 2006
    ..This review focuses on novel antithrombotic therapies for ACS, particularly fondaparinux sodium, a synthetic inhibitor of clotting factor Xa...
  2. ncbi request reprint Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
    ..More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose...
  3. doi request reprint Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, 326 Charles T Wethington Building, 900 South Limestone, Lexington, KY 40536 0293, USA
    J Thromb Thrombolysis 31:139-45. 2011
    ..3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event...
  4. pmc Salivary biomarkers associated with myocardial necrosis: results from an alcohol septal ablation model
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, and Lexington Veterans Administration Hospital, Lexington, Kentucky, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:616-23. 2012
    ..To determine if salivary biomarkers demonstrate utility for identifying aspects of myocardial necrosis...
  5. doi request reprint G-protein-coupled receptors as signaling targets for antiplatelet therapy
    Susan S Smyth
    Veterans Affairs Medical Center, Department of Medicine, Physiology, and Pharmacology, University of Kentucky, Lexington, KY, USA
    Arterioscler Thromb Vasc Biol 29:449-57. 2009
    ..The identification and development of new agents directed against specific platelet signaling pathways may offer an advantage in preventing thrombotic events while minimizing bleeding risk...
  6. ncbi request reprint Optimal management of hypertension in patients with ischemic heart disease
    Debabrata Mukherjee
    Gill Heart Institute and the Division of Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Cardiovasc Hematol Agents Med Chem 7:198-205. 2009
    ....
  7. pmc Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care?
    Eric L Wallace
    Division of Cardiovascular Medicine, Gill Heart Institute, and the College of Public Health, University of Kentucky, Lexington, KY 40536, USA
    South Med J 106:391-8. 2013
    ..Regional approaches have been developed with success and we sought to increase guideline compliance in Kentucky...
  8. pmc Oral fluids that detect cardiovascular disease biomarkers
    Joseph D Foley
    Department of Internal Medicine, Division of Cardiovascular Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky 40536 0297, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol 114:207-14. 2012
    ..The aim of this study was to determine the utility of oral fluids for assessment of coronary and cardiovascular (CV) health...
  9. ncbi request reprint Oral antiplatelet therapy for acute coronary syndromes: aspirin, P2Y12 inhibition and thrombin receptor antagonists
    Alison L Bailey
    Gill Heart Institute at University of Kentucky and Lexington Veterans Administration Hospital, Lexington, KY, USA
    Curr Drug Targets 12:1805-12. 2011
    ..This review summarizes ongoing efforts to improve the effectiveness of antiplatelet therapy among patients with ACS...
  10. pmc Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel
    Julie H Oestreich
    Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY 40536 0293, USA
    Coron Artery Dis 20:207-13. 2009
    ..Studies have shown that the mean aggregation response to clopidogrel can be changed by a higher maintenance dose. However, these studies have not focused on individual changes...
  11. pmc Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions
    Samy Selim
    Division of Cardiovascular Medicine, The Gill Heart Institute, 741 S Limestone Street, Lexington, KY 40536 0509, USA
    Clin Sci (Lond) 121:565-72. 2011
    ..Changes in S1P content may contribute to an RBC storage lesion. Further studies should investigate the clinical significance of alterations in circulating S1P levels and the potential value of enriching stored RBCs with S1P...
  12. doi request reprint Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease
    Fredric J Pashkow
    John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA
    Am J Cardiol 101:58D-68D. 2008
    ....
  13. ncbi request reprint Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag
    David J Moliterno
    J Am Coll Cardiol 49:2318-9. 2007
  14. ncbi request reprint Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel? An in vivo and vitro study
    Charles L Campbell
    Department of Cardiology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX, USA
    Am Heart J 150:796-9. 2005
    ..N-Acetylcysteine (NAC) is able to reduce disulfide bonds. We postulated that NAC might reverse clopidogrel's effect on platelets...